

The Evolving Management of Irritable Bowel Syndrome With Constipation: Pharmacists' Key Role in Improving Outcomes (Recorded Podcast)

KEY REFERENCES

1. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: management of irritable bowel syndrome. *Am J Gastroenterol*. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036
2. Harris LA, Chang CH. Burden of constipation: looking beyond bowel movements. *Am J Gastroenterol*. 2022;117(4S):S2-S5. doi:10.14309/ajg.0000000000001708
3. Yadav YS, Eslick GD, Talley NJ. Irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders. *Aliment Pharmacol Ther*. 2021;54(suppl 1):S24-S32. doi:10.1111/apt.16624
4. Barberio B, Savarino EV, Black CJ, Ford AC. Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: systematic review and meta-analysis. *Neurogastroenterol Motil*. 2022;34(6):e14279. doi:10.1111/nmo.14279
5. Galica AN, Galica R, Dumitraşcu DL. Diet, fibers, and probiotics for irritable bowel syndrome. *J Med Life*. 2022;15(2):174-179. doi:10.25122/jml-2022-0028
6. Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). *Am J Gastroenterol*. 2020;115(2):281-293. doi:10.14309/ajg.0000000000000516
7. Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). *Am J Gastroenterol*. 2021;116(6):1294-1303. doi:10.14309/ajg.0000000000001056
8. Lembo A, Chey WD, Rosenbaum DP. An open label long-term safety trial (T3MPO-3) of tenapanor in patients with irritable bowel syndrome with constipation (IBS-C). Presidential Poster Award 430. *Am J Gastroenterol*. 2018;113:s252.
9. Shah ED, Brenner DM, Chen VL. Baseline predictors of discontinuation of prescription drug therapy for IBS-C: cohort analysis at an integrated healthcare system. *Dig Dis Sci*. 2022;67(4):1213-1221. doi:10.1007/s10620-021-06963-x
10. Shah ED, Chang L, Salwen-Deremer JK, et al. Contrasting clinician and insurer perspectives to managing irritable bowel syndrome: multilevel modeling analysis. *Am J Gastroenterol*. 2021;116(4):748-757. doi:10.14309/ajg.0000000000000989
11. Shah ED, Chang L, Lembo A, Staller K, Curley MA, Chey WD. Price is right: exploring prescription drug coverage barriers for irritable bowel syndrome using threshold pricing analysis. *Dig Dis Sci*. 2021;66(12):4140-4148. doi:10.1007/s10620-020-06806-1
12. Liu JJ, Brenner DM. Current and future treatment approaches for IBS with constipation. *Aliment Pharmacol Ther*. 2021;54(suppl 1):S53-S62. doi:10.1111/apt.16607
13. Elwing JE, Atassi H, Rogers BD, Sayuk GS. Emerging therapies in the management of irritable bowel syndrome (IBS). *Expert Opin Emerg Drugs*. 2022;27(1):55-73. doi:10.1080/14728214.2022.2052043
14. Wechsler EV, Shah ED. Diarrhea-predominant and constipation-predominant irritable bowel syndrome: current prescription drug treatment options. *Drugs*. 2021;81(17):1953-1968. doi:10.1007/s40265-021-01634-7